Dr Reddy’s Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.
ITC shares rise 2% after Q2 results. What are Jefferies, Nuvama and others saying?
ITC shares gained 2% despite an 18.5% year-on-year decline in Q2 net profit, as higher taxes and falling cigarette earnings weighed on profitability. However, its
November 3, 2026